Literature DB >> 8675559

Low density lipoprotein particle size in hypopituitary adults receiving conventional hormone replacement therapy.

D O'Neal1, F L Hew, K Sikaris, G Ward, F Alford, J D Best.   

Abstract

Adults receiving conventional replacement therapy for hypopituitarism are known to have increased cardiovascular mortality. The aim of this study was to assess the lipid profiles of 30 hypopituitary adults compared with 2 case control groups, 1 matched for age, sex, and body mass index (BMI) and the second matched for age and sex only with a BMI representative of the general population. Fasting lipids, lipoproteins, and apoproteins (Apo) were determined by routine methods. Low density lipoprotein (LDL) particle size was determined by nondenaturing gradient gel electrophoresis. LDL size was significantly smaller in the hypopituitary group (25.9 +/- 0.1 nm) than in the BMI-matched (26.2 +/- 0.1 nm; P < 0.05) and standard control (26.3 +/- 0.1 nm; P < 0.01) groups. High density lipoprotein cholesterol levels in the hypopituitary group were significantly lower than those in the BMI-matched control group (1.13 +/- 0.06 vs. 1.34 +/- 0.06 mmol/L; P < 0.05) and the standard control group (1.38 +/- 0.06 mmol/L; P < 0.005). Apo A1 levels were also lower compared with those in the BMI-matched (122 +/- 6 vs. 137 +/- 4 mg/dL; P < 0.05) and the standard (143 +/- 4 mg/dL; P < 0.005) control groups. There was a trend toward higher triglyceride levels when the hypopituitary subjects were compared with the standard control group [1.4 (95% CI, 1.3-2.2) vs. 1.0 (95% CI, 0.9-1.4) mmol/L; P = 0.06]. These differences were more marked in the female subjects studied. No significant differences were noted in total cholesterol, LDL cholesterol, or Apo B levels. We conclude that hypopituitary patients receiving conventional replacement therapy have an atherogenic lipid profile characterized by small dense LDL, decreased high density lipoprotein cholesterol, and increased triglyceride levels, which may contribute to the excess cardiovascular mortality in this group.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675559     DOI: 10.1210/jcem.81.7.8675559

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Effects of GH replacement on metabolism and physical performance in GH deficient adults.

Authors:  S K Abdul Shakoor; S M Shalet
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

2.  Serum adipokines and low density lipoprotein subfraction profile in hypopituitary patients with growth hormone deficiency.

Authors:  Serpil Salman; Ayse Kubat Uzum; Aysegul Telci; Faruk Alagol; Nese Colak Ozbey
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

3.  The clinical biochemistry of obesity.

Authors:  Ken A Sikaris
Journal:  Clin Biochem Rev       Date:  2004-08

4.  Increased lipid peroxidation in adult GH-deficient patients: effects of short-term GH administration.

Authors:  M Scacchi; E Valassi; A I Pincelli; L M Fatti; F Pecori Giraldi; P Ascoli; R Viarengo; B Cestaro; F Cavagnini; R Cazzola
Journal:  J Endocrinol Invest       Date:  2006-11       Impact factor: 4.256

Review 5.  Growth hormone release during acute and chronic aerobic and resistance exercise: recent findings.

Authors:  Laurie Wideman; Judy Y Weltman; Mark L Hartman; Johannes D Veldhuis; Arthur Weltman
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

Review 6.  Arterial pulse wave velocity, inflammatory markers, pathological GH and IGF states, cardiovascular and cerebrovascular disease.

Authors:  Michael R Graham; Peter Evans; Bruce Davies; Julien S Baker
Journal:  Vasc Health Risk Manag       Date:  2008

Review 7.  Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile.

Authors:  Balázs Ratku; Veronika Sebestyén; Annamária Erdei; Endre V Nagy; Zoltán Szabó; Sándor Somodi
Journal:  Pituitary       Date:  2022-02-01       Impact factor: 4.107

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.